Not from any licensed seller. Retatrutide has no regulatory approval anywhere. No seller tracked on this desk lists it. A storefront borrowing the vocabulary is not selling the molecule. What exists instead is a gray market, and the evidence about it covers handling and detection rather than results.
The trial results are worth knowing anyway. They set the ceiling this market will eventually be priced against. The same distinction applies to the microdose tiers in the dose people actually stay on.
What was tested
A phase 2, double-blind, randomized trial enrolled 338 adults [1]. Entry was a BMI of 30 or more, or 27 to under 30 with a weight-related condition.
Assignment was weekly subcutaneous retatrutide at 1 mg, 4 mg, 8 mg or 12 mg, or placebo, for 48 weeks. The 4 mg and 8 mg levels each ran two different starting doses.
What it found
At 24 weeks, mean weight change was −7.2% at 1 mg and −12.9% in the combined 4 mg group. The combined 8 mg group reached −17.3% and the 12 mg group −17.5%, against −1.6% on placebo.
By 48 weeks those had become −8.7%, −17.1%, −22.8% and −24.2%, against −2.1%.
The threshold figures carry the result. On 12 mg at 48 weeks, every participant lost at least 5% of body weight. Ninety-three percent lost at least 10% and 83% at least 15%. On placebo the same three figures were 27%, 9% and 2%. Whether anyone stays on long enough to reach that is counted in about a third reach one year.
Somebody is already taking it
An antidoping laboratory published a detection and excretion method for retatrutide in human plasma and urine [2]. Laboratories build those methods when a substance turns up in samples. The paper gives a detection window of roughly two months.
A test exists for a drug no regulator has approved. That is the clearest evidence available that an unapproved molecule is circulating outside trials. The detail is in the excretion profile.
What the gray market actually ships
Peptide sites selling without a prescription ship no syringes and no instructions. Researchers watched twenty adults prepare gray-market peptide semaglutide using only what those sites provided [3]. Participants completed 15 of 34 steps correctly.
That study used semaglutide, which at least has a published reference dose. Retatrutide has none outside a trial protocol. The error rate on the easier problem is a floor, and the step-by-step breakdown shows where the chain broke. The same measurement problem appears in licensed compounded product, in the poison control case series.
What it means for anyone buying now
Nothing in this trial is for sale. Several storefronts sell compounded preparations under phrasing that gestures at the newest thing. Microdose tiers, combination vials, products named by mechanism rather than by molecule. None of those is retatrutide.
What the result changes is how a long commitment reads. Across the 381 injected tirzepatide figures recorded here the median billed rate is $249 a month, read September 2026. That is $2,988 for a year.
A twelve-month prepay buys at today’s prices. A stronger competitor is in late development, and prepaid money is usually not refundable. Read the term carefully, for the reason in the headline is not the bill. Then weigh it against what the economic studies measured.